Managing remnant cholesterol: role of fenofibrate–statin therapy in reducing triglyceride-rich lipoproteins - Report - MDSpire

Managing remnant cholesterol: role of fenofibrate–statin therapy in reducing triglyceride-rich lipoproteins

  • By

  • Vikrama Raja

  • Carlos Aguiar

  • Nasreen Alsayed

  • Yogeyaa S. Chibber

  • Hussein ElBadawi

  • Michel Farnier

  • Kumari Pushpa

  • Lale Tokgözoglu

  • Alberto Zambon

  • Jean-Pascal Berrou

  • Michel P. Hermans

  • June 4, 2026

  • 0 min

Share

Clinical Report: Addressing Remnant Cholesterol with Fenofibrate-Statin Therapy

Overview

This report discusses the role of remnant cholesterol (RC) as a significant risk factor for atherosclerotic cardiovascular disease (ASCVD) and the combination of fenofibrate with statin therapy to address residual cardiovascular risk.

Background

Dyslipidemia is a major contributor to ASCVD, and despite achieving target low-density lipoprotein cholesterol (LDL-C) levels with statin therapy, many patients still experience residual cardiovascular risk. Remnant cholesterol, derived from triglyceride-rich lipoproteins, has emerged as a target for reducing this risk.

Data Highlights

No specific numerical data provided in the source material.

Key Findings

  • Remnant cholesterol is an independent risk factor for ASCVD and should be a target for pharmacological intervention.
  • Statin therapy alone may not sufficiently reduce residual cardiovascular risk associated with elevated remnant cholesterol.
  • Fenofibrate, when combined with statins, has shown efficacy in lowering non-HDL-C levels.
  • Long-term studies support the safety and tolerability of fenofibrate as an adjunct therapy.

Clinical Implications

Clinicians should consider the role of remnant cholesterol in patients with residual cardiovascular risk despite optimal statin therapy.

Conclusion

Addressing remnant cholesterol through fenofibrate-statin combination therapy may enhance cardiovascular risk management in patients with dyslipidemia.

Related Resources & Content

  1. Clinical Research in Cardiology, Springer, 2026 -- Short-term lesion-level impact of extensive LDL-C reduction with statins and PCSK9 inhibitors: a pre-specified subgroup analysis of the randomized FITTER trial
  2. conexiant -- Can Liver-Only Targeting Change Lipids?
  3. conexiant -- ApoB Goal Cost-Effective in Primary Prevention
  4. European Journal of Preventive Cardiology -- Efficacy of obicetrapib across the spectrum of background lipid-lowering therapies: pooled analyses of the BROADWAY and BROOKLYN randomized trials
  5. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines | JACC
  6. Action to Control Cardiovascular Risk in Diabetes Lipid Trial - American College of Cardiology
  7. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines | JACC
  8. Action to Control Cardiovascular Risk in Diabetes Lipid Trial - American College of Cardiology
  9. Checking your browser - reCAPTCHA

Original Source(s)

Managing remnant cholesterol: role of fenofibrate–statin therapy in reducing triglyceride-rich lipoproteins

  • by Vikrama Raja, Carlos Aguiar, Nasreen Alsayed, Yogeyaa S. Chibber, Hussein ElBadawi, Michel Farnier, Kumari Pushpa, Lale Tokgözoglu, Alberto Zambon, Jean-Pascal Berrou, Michel P. Hermans

  • June 4, 2026

Related Content

An epidemiological assessment of the distribution and sociodemographic burden of chronic diseases: a focus on hypertension, diabetes, and cardiovascular conditions

Correction: Complete Blood Count–Derived Inflammation Indices to Predict 3-Year All-Cause Mortality in Patients With Diabetes and Acute Myocardial Infarction in Critical Care: Retrospective Cohort Study With Single-Center External Validation

Vitamin D: The Answer May Be Genetic

A post hoc D2d analysis found vitamin D3 supplementation was linked to lower diabetes risk only among patients with ApaI AC or CC genotypes.